⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144009 | 1.00 | CES2 (0.47) | — | |
| SCHEMBL3017645 | 1.00 | CES2 (0.47) | — | |
| SCHEMBL1144614 | 0.96 | — | — | |
| SCHEMBL609287 | 0.89 | — | — | |
| SCHEMBL10749 | 0.81 | — | — | |
| SCHEMBL21539010 | 0.79 | CES2 (0.47) | — | |
| SCHEMBL2189503 | 0.73 | — | — | |
| SCHEMBL9797512 | 0.73 | CES2 (0.43) | — | |
| SCHEMBL21180883 | 0.73 | CES2 (0.43) | — | |
| SCHEMBL9797502 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | claimed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | claimed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | claimed |
| EP-2881394-A1 | CONDENSED RING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-06-10 | — | — | EP | claimed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | claimed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | claimed |
| US-20080312206-A1 | Chemical Compounds-149 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-1966174-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071955-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-20060258690-A1 | Spiro-substituted pyrrologyrimidines | NOVARTIS AG (CH) | 2006-11-16 | — | — | US | claimed |
| EP-1601677-B1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2006-06-28 | — | — | EP | claimed |
| EP-1601677-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | Novartis AG (CH) | 2005-12-07 | — | — | EP | claimed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | claimed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3877383-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | The University of Melbourne (AU) | 2021-09-15 | — | — | EP | disclosed |
| CN-113272298-A | Compounds and compositions for the treatment of respiratory diseases | 墨尔本大学 | 2021-08-17 | — | — | CN | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |